Fentanyl, PTSD Symptoms, and a Five-Day Authorization
Marcus is a 34-year-old man referred by the emergency department after his second naloxone reversal in 12 months. He has used smoked fentanyl daily for six years, completed residential treatment twice (both relapses within 60 days), and has been abstinent 8 days, mostly because he is staying with his sister, who also uses and has asked him to leave by Friday. ASAM intake findings: COWS 6 with mild anxiety and insomnia, no acute medical needs; hepatitis C antibody positive, never linked to care; PCL-5 = 58 with nightmares and hypervigilance stemming from a 2019 assault; PHQ-9 = 19; passive suicidal ideation two weeks ago with no current plan or intent and no firearm access. He is unemployed, has no transportation, and has a pending felony possession charge. The payer authorizes 5 days of residential followed by partial hospitalization. Your assessment supports ASAM Level 3.5.
1. Determine the appropriate level of care and justify it dimension by dimension, including where your assessment and the payer's authorization diverge.
Read the worked answer
Conclusion: Level 3.5 is defensible, but not because of withdrawal - the withdrawal picture is mild (COWS 6) and would not by itself require residential care.
- Dimension 1 (withdrawal/intoxication): Mild; supports 2-WS or outpatient withdrawal management. Not the driver.
- Dimension 2 (biomedical): HCV untreated is a linkage and care-coordination issue, not an acute residential need.
- Dimension 3 (psychiatric): PCL-5 of 58, PHQ-9 of 19, and recent passive ideation with two prior relapses make 24-hour structure clinically indicated. This is the strongest justification.
- Dimension 4 (readiness): Ambivalent; external pressure exists but insight is limited, so containment plus engagement is appropriate.
- Dimension 5 (relapse potential): High - two overdoses, two failed residential episodes, and 8 days of abstinence in an actively using household.
- Dimension 6 (recovery environment): Very high risk: imminent loss of housing, no transportation, pending felony charge.
Divergence: The payer appears to be paying for withdrawal management duration while you are treating psychiatric risk and environmental instability. That mismatch is what the concurrent review must address, using the dimension-specific evidence rather than a global severity label.
2. Sequence PTSD-focused treatment relative to SUD stabilization. What would you start now, what would you defer, and why?
Read the worked answer
Start now, during the 5-day stay:
- Safety planning and suicide risk monitoring with documented reassessment.
- Psychoeducation framing nightmares, hypervigilance, and avoidance as trauma symptoms that craving and withdrawal amplify.
- Sleep and grounding skills (the insomnia is a relapse risk and a PTSD symptom).
- Medication evaluation: an SSRI is reasonable; benzodiazepines are not, given the OUD history.
- Naltrexone discussion and overdose-prevention education, including naloxone for his sister's household.
Defer: Formal trauma-focused protocols (prolonged exposure, cognitive processing therapy) that require stable sobriety, homework capacity, and reliable session attendance. Beginning exposure in week one of a 5-day stay with unstable housing and active passive ideation risks retraumatization and dropout.
Reasoning: Integrated care is preferable to a strict sequential rule - the client should not be told to 'come back in a year' for trauma work - but the dose and timing of exposure must follow stabilization. Plan trauma-focused treatment to begin once he is in PHP, has 3–4 weeks of abstinence and a settled residence, and coping skills are demonstrably in use. Document the deferral as a clinical decision with criteria for revisiting, not as an omission.
3. Write the medical-necessity justification and concurrent-review strategy for the 5-day authorization. What evidence do you document?
Read the worked answer
Frame the request in ASAM language, not adjectives. Cite the specific dimension findings: COWS score, PCL-5 and PHQ-9 scores, date and content of the ideation screen, overdose count and dates, housing loss date, and legal status.
Concurrent review strategy:
- Call the payer reviewer before day 3 rather than on day 5; same-day discharge appeals rarely succeed.
- Request a peer-to-peer with a clinician reviewer and offer the assessment summary in advance.
- Anticipate the objection ('withdrawal is mild') and answer it directly: the request is not for withdrawal management but for 24-hour psychiatric monitoring and removal from an actively using household.
- Simultaneously build the step-down plan (PHP placement, transportation voucher, HCV linkage, sober living referral) so the reviewer sees a transition, not an open-ended stay.
Documentation to attach or reference: risk assessment with reassessments, nursing observations, prior treatment failures and dates, housing timeline, and the treatment plan showing which goals require residential intensity.
Reasoning: Authorization is a clinical-communication task. Vague severity claims get denied; dimension-anchored, time-stamped evidence with a discharge trajectory gets approved. If the payer still refuses, appeal in writing and document the clinical risk of the shorter level of care.